5271-26-1

Basic information

• Product Name: 2-Phenylpiperazine
• Synonyms: 2-PHENYLPIPERAZINE;2-Phenylpiperazine 97%;Piperazine, 2-phenyl-
• CAS NO: 5271-26-1
• Molecular Formula: C₁₀H₁₄N₂
• Molecular Weight: 162.23
• EINECS: 1308068-626-2
• Product Categories: pharmacetical;Piperaizine;Piperazine derivates;Building Blocks;Heterocyclic Building Blocks;Piperazines
• Mol File: 5271-26-1.mol

Chemical Properties

• Melting Point: 83-87 °C(lit.)
• Boiling Point: 289.2 °C at 760 mmHg
• Flash Point: 169 °C
• Appearance: /
• Density: 0.997 g/cm³
• Vapor Pressure: 0.00223mmHg at 25°C
• Refractive Index: 1.521
• PKA: 8.80±0.40(Predicted)
• CAS DataBase Reference: 2-Phenylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenylpiperazine(5271-26-1)
• EPA Substance Registry System: 2-Phenylpiperazine(5271-26-1)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-36/37/38
• Safety Statements: 26-36/37
• RIDADR: UN3259
• WGK Germany: 2
• HazardClass: IRRITANT
• Hazardous Substances Data: 5271-26-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Phenylpiperazine is used as a starting material for the synthesis of various 2-phenylpiperazine compounds, which have a wide range of applications in the pharmaceutical industry. These synthesized compounds can exhibit diverse pharmacological activities, such as acting as antidepressants, anxiolytics, and antipsychotics. The structural flexibility of 2-phenylpiperazine allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-Phenylpiperazine serves as a key intermediate for the creation of a variety of complex organic molecules. Its unique structure allows for further functionalization and modification, leading to the development of new compounds with specific properties and applications in various industries, such as materials science, agrochemicals, and dyes.
Some specific examples of synthesized compounds from 2-Phenylpiperazine include:
1. 1,4-Dimethyl-2-phenylpiperazine: 2-Phenylpiperazine has been synthesized for its potential applications in the pharmaceutical industry, particularly as a precursor to drugs with central nervous system activity.
2. 1,4-Diethyl-2-phenylpiperazine: Similar to its dimethyl counterpart, 2-Phenylpiperazine is also synthesized for its potential use in the development of pharmaceuticals, with a focus on compounds that target the central nervous system.

InChI:InChI=1/C10H14N2/c1-2-4-9(5-3-1)10-8-11-6-7-12-10/h1-5,10-12H,6-8H2

Upstream product

• 93-56-1 phenylethane 1,2-diol 
• 107-15-3 ethylenediamine 
• 1203590-16-2 4-hydroxy-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester 
• 5368-34-3 (+/-)-1,4-dibenzyl-2-phenylpiperazine 
• 100-42-5 styrene 
• 1421004-96-7 C₂₀H₃₀N₂O₄ 
• 4870-65-9 2-bromophenylacetic acid 
• 2882-19-1 ethyl 2-phenyl-2-bromoacetate 
• 1083195-99-6 5-phenylpiperazine-2,3-dione 
• 5700-56-1 1,2-diaminophenylethane 
• 15028-40-7 DL-2-phenylglycine methyl ester hydrochloride 
• 700-63-0 Phenylglycinamid 
• 1074-12-0 phenylglyoxal hydrate 
• 5368-28-5 2-phenyl-3-keto-piperazine 

Downstream Products

• 116162-77-7 1-tert-Butyl-6-fluoro-4-oxo-7-(3-phenyl-piperazin-1-yl)-1,4-dihydro-quinoline-3-carboxylic acid 
• 141543-66-0 5-(3-Phenyl-piperazine-1-sulfonyl)-isoquinoline; hydrochloride 
• 125197-43-5 1-tert-Butyl-6-fluoro-4-oxo-7-(3-phenyl-piperazin-1-yl)-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid 
• 185108-03-6 (+,)-4-[[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-phenyl-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]acetyl]piperazine 
• 185110-03-6 1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-phenyl-piperazine 
• 942123-05-9 1-(4-bromo-benzyl)-3-phenyl-piperazine 
• 1058130-66-7 C₃₉H₄₅N₅O₅S 
• 1010739-50-0 C₂₁H₂₀N₆ 

Relevant articles and documents

A simple one-pot method for the mercuric oxide mediated synthesis of piperazines via oxidative diamination of olefins

Mercuric oxide mediated one-pot synthesis of substituted piperazines via oxidative diamination of olefins with N-protected ethylene diamine has been reported. Among the various conditions tried, mercuric(II)oxide/tetrafluoroboric acid gave good to excellent yields of the desired products. A series of piperazines have been synthesized and characterized by NMR and mass spectroscopy methods.

Iridium-catalyzed condensation of amines and vicinal diols to substituted piperazines

A straightforward procedure is described for the synthesis of piperazines from amines and 1,2-diols. The heterocyclization is catalyzed by [Cp*IrCl2]2 and sodium hydrogen carbonate and can be achieved with either toluene or water as solvent. The transformation does not require any stoichiometric additives and only produces water as the byproduct. The reaction can be performed between a 1,2-diamine and a 1,2-diol or by a double condensation between a primary alkylamine and a 1,2-diol. At least one substituent is required on the piperazine ring to achieve the cyclization in good yield. The mechanism is believed to involve dehydrogenation of the 1,2-diol to the α-hydroxy aldehyde, which condenses with the amine to form the α-hydroxy imine. The latter rearranges to the corresponding α-amino carbonyl compound, which then reacts with another amine followed by reduction of the resulting imine. Piperazines are prepared by [Cp*IrCl 2]2-catalyzed heterocyclization of 1,2-diols with either 1,2-diamines or primary alkylamines. The reaction is performed in toluene or water and requires no stoichiometric additive. The key step in the mechanism is believed to be the isomerization of an α-hydroxy imine to the corresponding α-amino carbonyl compound. Copyright

COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS

Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses as IDH1 mutants inhibitors for treating cancers are also provided

Complete regioselective addition of grignard reagents to pyrazine N-oxides, toward an efficient enantioselective synthesis of substituted piperazines

(Figure presented) A conceptually new one-pot strategy for the synthesis of protected substituted piperazines via the addition of Grignard reagents to pyrazine N-oxides is presented. This strategy is high yielding (33-91% over three steps), step-efficient, and fast. The synthesized N,N-diprotected piperazines are convenient to handle and allow for orthogonal deprotection at either nitrogen for selective transformations. In addition, this Is a synthetic route to enantiomerically enriched piperazines by using a combination of phenyl magnesium chloride and (-)-sparteine, which resulted In enantiomeric excesses up to 83%.

AMIDO-THIOPHENE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

Iridium catalysed synthesis of piperazines from diols

A green and atom-economical method has been developed for the synthesis of piperazines by cyclocondensation of diols and amines in aqueous media in the presence of a catalytic amount of [Cp*IrCl2]2. The Royal Society of Chemistry.

COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein, R1, R2, A, Y, X, Ar1 and Ar2 have the meanings given in the specification, and the preparation and use thereof. The compounds are valuable CB2 receptor modulators.

Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process

Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: wherein: n is an integer of 1 to 6; X, Y, Z1 and Z2 can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C1-C6) alkoxy, N-alkyl,(C2-C6) acyloxy, N-alkylene, —SH, —SR, wherein R is from the same group as R1 and R2 and can be the same or different than R1 and R2, amino, nitro, cyano, hydroxy, C(═O) OR6, —C(═O) NR5R4, NR3R2, or S(αO)k R1 wherein k is 1 or 2, and R1 to R6 are independently hydrogen or (C1-C6) alkyl; R1, and R2 can be the same or different and are hydrogen, (C1-C6) alkyl, hydroxyalkyl or mercaptoalkyl, —C(═O) OR1, cyano, (C1-C6) alkenyl, (C2-C6) alkynyl, or 1,2,4-oxadiazol-5-yl optionally substituted at the 3-position by Z4 wherein any (C1-C6) alky, (C1-C6) alkanoyl, (C2-C6) alkenyl or (C2-C6) alkynyl can optionally be substituted by 1, 2 or 3 Z; R7 can be hydrogen, O or phenyl R8 can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl Z4 is (C1-C6) alkyl or phenyl, optionally substituted by 1, 2 or 3 Z1 W is O or S T is amino or C1-C6 aminoalkyl A is N or C T is C1-C6 alklyl or sulfonyl and V is alkyl (C0-C6), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R1 or R2 as indicated above and φ is phenyl, naphthyl, thienyl or pyridinyl.

DIAGNOSTIC AND THERAPEUTIC ALKYL PIPERIDINE/PIPERAZINE COMPOUNDS AND PROCESS

Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: (I), (II), (III), (IV), (V) wherein: n is an integer of 1 to 6; X, Y, Z1 and Z2 can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C1-C6)alkoxy, N-alkyl, (C2-C6)acyloxy, N-alkylene, -SH, -SR, wherein R is from the same group as R1 and R2 and can be the same or different than R1 and R2, amino, nitro, cyano, hydroxy, C(=O)OR6, -C(=O)NR5R4, NR3R2, or S(=O)kR1 wherein k is 1 0r 2, and R1 to R6 are independently hydrogen or (C1-C6)alkyl; R1 and R2 can be the same or different and are hydrogen, (C1-C6)alkyl, hydroxyalkyl or mercaptoalkyl, -C(=O)OR1, cyano, (C1-C6)alkenyl, (C2-C6) alkynyl, or 1, 2, 4-oxadiazol-5-yl optionally substituted at the 3-position by Z4 wherein any (C1-C6)alky, (C1-C6)alkanoyl, (C2-C6)alkenyl or (C2-C6)alkynyl can optionally be substituted by 1, 2 or 3 Z; R7 can be hydrogen, O or phenyl; R8 can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl; Z4 is (C1-C6)alkyl or phenyl, optionally substituted by 1, 2 or 3 Z1; W is O or S; T is amino or C1-C6aminoalkyl; A is N or C; T is C1-C6alkyl or sulfonyl and V is alkyl (C0-C6), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R1 or R2 as indicated above and D is phenyl, naphrhyl, thienyl or pyridinyl.

PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE

The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (whereinR1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like,R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like,R5: hydrogen, a lower alkyl, a lower alkoxycarbonyl, or the like, andn: 0 or 1).